Register Login

RHYTHM PHARMACEUTICALS, INC. (RYTM)

(90% Positive) RHYTHM PHARMACEUTICALS, INC. (RYTM) Announces Enrollment Update for opportunity Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot March 26, 2026, 8:07 p.m.

    📋 RHYTHM PHARMACEUTICALS, INC. (RYTM) - Clinical Trial Update

    Filing Date: 2026-03-26

    Accepted: 2026-03-26 16:06:16

    Event Type: Clinical Trial Update

    Event Details:

    RHYTHM PHARMACEUTICALS, INC. (RYTM) Announces Clinical Trial Update RHYTHM PHARMACEUTICALS, INC. (RYTM) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: opportunity, anticipated
    • Diseases/Conditions: Acquired, Rhythm which we are well positioned to execute on
    • Collaboration: FDA
      • anticipated in second quarter of 2026
      • anticipated in the second quarter of 2026

    🔬 Clinical Development Pipeline (RHYTHM PHARMACEUTICALS, INC.):

    Product Type Development Stage Therapeutic Area Source
    SC Placebo DRUG Phase PHASE4 Healthy ClinicalTrials.gov
    Bivamelagon DRUG Phase PHASE2 Hypothalamic Obesity ClinicalTrials.gov
    RM-493 DRUG Phase PHASE1 Overweight ClinicalTrials.gov
    Setmelanotide, administered subcutaneously [SC], once daily. DRUG Preclinical Bardet-Biedl Syndrome (BBS) ClinicalTrials.gov
    Oral Placebo DRUG Phase PHASE4 Healthy ClinicalTrials.gov
    Moxifloxacin DRUG Phase PHASE4 Healthy ClinicalTrials.gov
    Setmelanotide 30 mg DRUG Phase PHASE3 Bardet-Biedl Syndrome ClinicalTrials.gov
    Setmelanotide 25 mg DRUG Phase PHASE3 Bardet-Biedl Syndrome ClinicalTrials.gov
    Setmelanotide 20 mg DRUG Phase PHASE3 Bardet-Biedl Syndrome ClinicalTrials.gov
    Setmelanotide 3 mg DRUG Phase PHASE3 Bardet-Biedl Syndrome ClinicalTrials.gov
    Setmelanotide 2.5 mg DRUG Phase PHASE3 Bardet-Biedl Syndrome ClinicalTrials.gov
    Setmelanotide 2 mg DRUG Phase PHASE3 Bardet-Biedl Syndrome ClinicalTrials.gov
    Part C: RM-718 DRUG Phase PHASE1 Hypothalamic Obesity ClinicalTrials.gov
    Part B: RM-718 or placebo (matched to specific RM-718 dose cohort) DRUG Phase PHASE1 Hypothalamic Obesity ClinicalTrials.gov
    Part A: RM-718 or placebo (matched to specific RM-718 dose cohort) DRUG Phase PHASE1 Hypothalamic Obesity ClinicalTrials.gov
    LB54640 DRUG Phase PHASE2 Hypothalamic Obesity ClinicalTrials.gov
    Placebo DRUG Phase PHASE3 Hypothalamic Obesity ClinicalTrials.gov
    Setmelanotide DRUG Phase PHASE2 Prader-Willi Syndrome ClinicalTrials.gov
    LB-102 DRUG Phase PHASE3 Schizophrenia ClinicalTrials.gov
    LB-102 (100 mg tablet) DRUG Phase PHASE3 Schizophrenia ClinicalTrials.gov
    LB-102 (50 mg tablet) DRUG Phase PHASE3 Schizophrenia ClinicalTrials.gov
    Part D: RM-718 DRUG Phase PHASE1 Hypothalamic Obesity ClinicalTrials.gov
    Collagenase Clostridium Histolyticum (CCH) BIOLOGICAL Phase PHASE2 Plantar Fasciitis ClinicalTrials.gov

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: RHYTHM PHARMACEUTICALS, INC.
    • Ticker Symbol: RYTM

Search

News categories